who should not take glp-1 I in the Morning or at Night? who should not take glp-1

Mild side effects (water retention, tingling, slight hunger increase) don't require stopping

Key Takeaways MT1 (afamelanotide) is FDA-approved (2019) and EMA-approved (2014) for erythropoietic protoporphyria under the brand name Scenesse

Patton EE, Widlund HR, Kutok JL, Kopani KR, Amatruda JF, Murphey RD et al

Visceral adiposity contributes to chronic low-grade inflammation through macrophage activation, altered T-cell responses, and adipokine imbalance ( Beyond obesity, insulin resistance and hyperinsulinemia appear to play an active role in sustaining inflammatory arthritis rather than representing mere epiphenomena of chronic inflammation